Skip to main content

Gilead Analysts Dissect Immunomedics Deal: 'Pricier But Bold Move Into...

Gilead Analysts Dissect Immunomedics Deal: 'Pricier But Bold Move Into... image

Gilead Analysts Dissect Immunomedics Deal: 'Pricier But Bold Move Into Oncology' - Benzinga

Gilead Sciences, Inc. (NASDAQ: GILD) announced over the weekend a deal to buy Immunomedics, Inc. (NASDAQ: IMMU), which recently transitioned to a ...
Read More

In Similar Category

From Benzinga